White, D. L., Radich, J., Soverini, S., Saunders, V. A., Frede, A. K., Dang, P., Cilloni, D., Lin, P., Mongay, L., Woodman, R., Manley, P., Slader, C., Kim, D. W., Pane, F., Martinelli, G., Saglio, G. and Hughes, T. P. (2012) “Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib”, Haematologica. Pavia, Italy, 97(6), pp. 907-914. doi: 10.3324/haematol.2011.056457.